Generic treatments for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, TB could be mass-produced for &lt;$90 per patient

Hill, Alison L.; Barber, Melissa; Gotham, Dzintars; Fortunak, J.; Pozniak, A.

doi:10.1016/s0168-8278(17)30888-7

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hill et al 29 have reported that the lowest current global price for ledipasvir-sofosbuvir is USD $307. This is significantly less than 16.40% of the patented cost of ledipasvir-sofosbuvir (£6,392.72).…”

Section: Discussionmentioning

confidence: 99%

“…In 2017, the lowest global price was observed to have reduced to USD $307 for ledipasvir-sofosbuvir and USD $108 for daclatasvir-sofosbuvir. 29 Therefore, the percentage of the current drug price that generic drugs might enter the market at was a key focus in sensitivity analysis. Many hepatitis C combination therapy drugs are expected to begin to reach patent expiry in 2030.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

Heath

2018

CEOR

View full text Add to dashboard Cite

BackgroundCost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to generic drug introduction.MethodsAn existing mathematical model by Shih et al was extended to consider lower-cost future generics in health economic models of hepatitis C. The model compared the cost-effectiveness of treating patients now with patented drugs vs postponing treatment until after patent expiration.ResultsFor ledipasvir-sofosbuvir, this study finds that it is almost always more cost effective to treat hepatitis C with high-cost patented drugs immediately rather than waiting for patent expiry. For ledipasvir-sofosbuvir, a generic would need to enter the market at <16.40% of the patented price for delayed treatment to be cost effective. The further that patent expiry is in the future, the more cost effective delayed treatment becomes; however, uncertainty about generic pricing and market entry times are also higher if patent expiry is in the distant future.ConclusionIt is more cost effective to treat hepatitis C sooner rather than later, regardless of the stage of the disease, and despite the high cost of patented drugs. However, patented drugs are being produced globally for prices much lower than those seen in the UK. Therefore, negotiation of patented drug prices with pharmaceutical companies may be a crucial step in cost effective treatment of hepatitis C.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%